Astrazeneca Pharma India Ltd.
Fundamentals
- Market cap
- ₹20,978 cr
- P/E
- 111.87×
- ROE
- 15.02%
- Debt / equity
- 0.00
- Div yield
- 0.43%
- 52-week range
- 7551.50 — 9849.50
Company snapshot
Astrazeneca Pharma India Ltd.
Pharmaceuticals
₹20,957 cr
P/E 111.76×
Latest quarter · Mar 2026
Sales₹579 cr
Net profit₹45 cr
Op. margin+10.5%
EPS₹17.95
Strength & growth
Debt / equity0.00×
Current ratio1.70×
Sales CAGR+15.0%
EPS CAGR+43.1%
The timeline — 4 notes on Astrazeneca Pharma India Ltd.
May 2026
- 26 May 26 · 7:50 PM IST Brief Brief · Earnings · Large cap
AstraZeneca Pharma India revenue climbs 33% on oncology drug launches
The company posted a net profit of ₹1.9 billion for FY26, supported by 11 new regulatory approvals and a dividend recommendation of ₹36 per share.
- 26 May 26 · 7:17 PM IST Brief Brief · Earnings · Large cap
AstraZeneca Pharma India profit rises to ₹1.9 billion
Revenue hit ₹22.8 billion for FY26 as oncology sales grew. The board recommended a final dividend of ₹36 per share.
- 21 May 26 · 1:27 PM IST Lead Lead · Large cap
AstraZeneca India wins CDSCO nod for Calquence in MCL
Second Indian approval for BTK inhibitor after CLL; broadens addressable patient pool in aggressive lymphoma.